Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein

David Jeng, Masmudur Rahman, Douglas McFadden, Karim Essani

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Viruses have evolved strategies to counteract host defenses. Some tactics employ viral proteins to neutralize host immune effector proteins such as cytokines, chemokines and their receptors, which help coordinate the host responses against the virus. Tumor necrosis factor (TNF) is one of the crucial pro-inflammatory/anti-viral cytokines involved in inflammatory and autoimmune diseases. Poxvirus anti-immune proteins represent some of the most complex and efficient mechanisms of regulating TNF and its pathological effects. These proteins have considerable potential for treating TNF-related diseases. Here we discuss two major classes of poxvirus-TNF inhibitors focusing on the tanapoxvirus (TPV)-2L protein, previously called TPV-gp38. TPV-2L has been shown to interact and biologically neutralize human (h)TNF, and has been indirectly associated with the inhibition of other cytokines (hIFN-γ, hIL-2 and hIL-5). The TPV-2L protein alone has been expressed, purified and shown to bind with high affinity to hTNF, but lacked binding to the other cytokines. Further studies identified sequential binding of hβ2-microglobulin and hα2-macroglobulin to TPV-2L. The ability of a single viral protein to form multi-protein complexes suggests that TPV might also possess other novel strategies of evading the immune system. Reviewed here are patented poxvirus TNF-binding proteins and their genes to evaluate their potential therapeutic value.

Original languageEnglish (US)
Pages (from-to)97-103
Number of pages7
JournalRecent Patents on DNA and Gene Sequences
Volume5
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Poxviridae
Tumor Necrosis Factor-alpha
Cytokines
Proteins
Viral Proteins
Viruses
Macroglobulins
Chemokine Receptors
Autoimmune Diseases
Immune System
Carrier Proteins
Genes

Keywords

  • Cytokines
  • Immune evasion
  • Inflammation
  • Poxvirus
  • Tumor necrosis factor
  • Viroceptors

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology
  • Genetics(clinical)

Cite this

Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein. / Jeng, David; Rahman, Masmudur; McFadden, Douglas; Essani, Karim.

In: Recent Patents on DNA and Gene Sequences, Vol. 5, No. 2, 01.08.2011, p. 97-103.

Research output: Contribution to journalArticle

@article{8c640a6efbcb4454b33cb0cbb59767f4,
title = "Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein",
abstract = "Viruses have evolved strategies to counteract host defenses. Some tactics employ viral proteins to neutralize host immune effector proteins such as cytokines, chemokines and their receptors, which help coordinate the host responses against the virus. Tumor necrosis factor (TNF) is one of the crucial pro-inflammatory/anti-viral cytokines involved in inflammatory and autoimmune diseases. Poxvirus anti-immune proteins represent some of the most complex and efficient mechanisms of regulating TNF and its pathological effects. These proteins have considerable potential for treating TNF-related diseases. Here we discuss two major classes of poxvirus-TNF inhibitors focusing on the tanapoxvirus (TPV)-2L protein, previously called TPV-gp38. TPV-2L has been shown to interact and biologically neutralize human (h)TNF, and has been indirectly associated with the inhibition of other cytokines (hIFN-γ, hIL-2 and hIL-5). The TPV-2L protein alone has been expressed, purified and shown to bind with high affinity to hTNF, but lacked binding to the other cytokines. Further studies identified sequential binding of hβ2-microglobulin and hα2-macroglobulin to TPV-2L. The ability of a single viral protein to form multi-protein complexes suggests that TPV might also possess other novel strategies of evading the immune system. Reviewed here are patented poxvirus TNF-binding proteins and their genes to evaluate their potential therapeutic value.",
keywords = "Cytokines, Immune evasion, Inflammation, Poxvirus, Tumor necrosis factor, Viroceptors",
author = "David Jeng and Masmudur Rahman and Douglas McFadden and Karim Essani",
year = "2011",
month = "8",
day = "1",
doi = "10.2174/187221511796392033",
language = "English (US)",
volume = "5",
pages = "97--103",
journal = "Recent patents on DNA & gene sequences",
issn = "2352-0922",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein

AU - Jeng, David

AU - Rahman, Masmudur

AU - McFadden, Douglas

AU - Essani, Karim

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Viruses have evolved strategies to counteract host defenses. Some tactics employ viral proteins to neutralize host immune effector proteins such as cytokines, chemokines and their receptors, which help coordinate the host responses against the virus. Tumor necrosis factor (TNF) is one of the crucial pro-inflammatory/anti-viral cytokines involved in inflammatory and autoimmune diseases. Poxvirus anti-immune proteins represent some of the most complex and efficient mechanisms of regulating TNF and its pathological effects. These proteins have considerable potential for treating TNF-related diseases. Here we discuss two major classes of poxvirus-TNF inhibitors focusing on the tanapoxvirus (TPV)-2L protein, previously called TPV-gp38. TPV-2L has been shown to interact and biologically neutralize human (h)TNF, and has been indirectly associated with the inhibition of other cytokines (hIFN-γ, hIL-2 and hIL-5). The TPV-2L protein alone has been expressed, purified and shown to bind with high affinity to hTNF, but lacked binding to the other cytokines. Further studies identified sequential binding of hβ2-microglobulin and hα2-macroglobulin to TPV-2L. The ability of a single viral protein to form multi-protein complexes suggests that TPV might also possess other novel strategies of evading the immune system. Reviewed here are patented poxvirus TNF-binding proteins and their genes to evaluate their potential therapeutic value.

AB - Viruses have evolved strategies to counteract host defenses. Some tactics employ viral proteins to neutralize host immune effector proteins such as cytokines, chemokines and their receptors, which help coordinate the host responses against the virus. Tumor necrosis factor (TNF) is one of the crucial pro-inflammatory/anti-viral cytokines involved in inflammatory and autoimmune diseases. Poxvirus anti-immune proteins represent some of the most complex and efficient mechanisms of regulating TNF and its pathological effects. These proteins have considerable potential for treating TNF-related diseases. Here we discuss two major classes of poxvirus-TNF inhibitors focusing on the tanapoxvirus (TPV)-2L protein, previously called TPV-gp38. TPV-2L has been shown to interact and biologically neutralize human (h)TNF, and has been indirectly associated with the inhibition of other cytokines (hIFN-γ, hIL-2 and hIL-5). The TPV-2L protein alone has been expressed, purified and shown to bind with high affinity to hTNF, but lacked binding to the other cytokines. Further studies identified sequential binding of hβ2-microglobulin and hα2-macroglobulin to TPV-2L. The ability of a single viral protein to form multi-protein complexes suggests that TPV might also possess other novel strategies of evading the immune system. Reviewed here are patented poxvirus TNF-binding proteins and their genes to evaluate their potential therapeutic value.

KW - Cytokines

KW - Immune evasion

KW - Inflammation

KW - Poxvirus

KW - Tumor necrosis factor

KW - Viroceptors

UR - http://www.scopus.com/inward/record.url?scp=79959932581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959932581&partnerID=8YFLogxK

U2 - 10.2174/187221511796392033

DO - 10.2174/187221511796392033

M3 - Article

C2 - 21529335

AN - SCOPUS:79959932581

VL - 5

SP - 97

EP - 103

JO - Recent patents on DNA & gene sequences

JF - Recent patents on DNA & gene sequences

SN - 2352-0922

IS - 2

ER -